Keiran S. M. Smalley

XL888 Limits Vemurafenib-Induced Proliferative Skin Events by Suppressing Paradoxical MAPK Activation.

BRAF Inhibition Generates a Host-Tumor Niche that Mediates Therapeutic Escape.

Pharmacological research and precision cancer medicine: A call for manuscripts.

Combination Therapies for Melanoma: A New Standard of Care?

The role of phenotypic plasticity in the escape of cancer cells from targeted therapy.

Increased immunity and BRAF inhibition: Yet another argument for combination therapy?

Ceritinib Enhances the Efficacy of Trametinib in -Wild-Type Melanoma Cell Lines.

The Blood Brain Barrier and BRAF inhibitors: Implications for patients with melanoma brain metastases.

Get with the Program! Stemness and Reprogramming in Melanoma Metastasis.

The biology and therapeutic management of melanoma brain metastases.

ERK Inhibition: A New Front in the War against MAPK Pathway-Driven Cancers?

Combined BRAF and HSP90 Inhibition in Patients with Unresectable -Mutant Melanoma.

HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy.

Pharmacological research and cancer: A call to arms.

HDAC Inhibition Enhances the Efficacy of MEK Inhibitor Therapy in Uveal Melanoma.

Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma.

Translational pathology, genomics and the development of systemic therapies for acral melanoma.

Proteomic Analysis of CSF from Patients with Leptomeningeal Melanoma Metastases Identifies Signatures Associated with Disease Progression and Therapeutic Resistance.

Two Worlds Collide: Unraveling the Role of the Immune System in BRAF-MEK Inhibitor Responses.

MEK-ing the most of it: strategies to co-target Gαq and MAPK in uveal melanoma.

Targeted Therapy Given after Anti-PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity.

Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases.

Ironing-Out the Details: New Strategies for Combining Ferroptosis Inhibitors with Immunotherapy in Melanoma.

HDAC11 activity contributes to MEK inhibitor escape in uveal melanoma.

Acral melanoma: new insights into the immune and genomic landscape.

HDAC8-mediated inhibition of EP300 drives a transcriptional state that increases melanoma brain metastasis.

Differential requirements for CD4+ T cells in the efficacy of the anti-PD-1+LAG-3 and anti-PD-1+CTLA-4 combinations in melanoma flank and brain metastasis models.